[1] Khan MAB, Hashim MJ, King JK, et al.Epidemiology of type 2 diabetes-global burden of disease and forecasted trends[J]. J Epidemiol Glob Health, 2020, 10(1):107-111.
[2] 朱婧,蒋晓红,项守奎,等. 1型糖尿病患者尿酸水平与血脂异常的相关性研究[J]. 国际内分泌代谢杂志, 2020, 40(1): 16-20.
[3] LeRoith D. Hyperglycemia, hypertension, and dyslipidemia in type 2 diabetes mellitus: Goals for diabetes management[J]. Clin Cornerstone, 2008, 9(Suppl 2): S8-S16.
[4] 文莉琳,赵忠霞,冯雄萍,等. 中老年体检人群血糖水平与血脂相关性分析[J]. 宁夏医学杂志, 2021, 43(12): 1197-1199.
[5] Jialal I.Management of diabetic dyslipidemia: Navigating the new American and European Guidelines[J]. Diabetes Metab Syndr, 2020, 14(5): 877-879.
[6] 左惠芬,商小丽,左惠娟. 18~44岁门诊就诊者空腹血糖及血脂化验结果分析[J]. 现代预防医学, 2016, 43(10): 1907-1909,1914.
[7] Dake AW, Sora ND.Diabetic dyslipidemia review: An update on current concepts and management guidelines of diabetic dyslipidemia[J]. Am J Med Sci, 2016, 351(4): 361-365.
[8] 陈灯塔. 应用经济计量学: EViews高级讲义[M]. 北京大学出版社, 2012: 385-387.
[9] Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in diabetes[J]. Best Pract Res Clin Endocrinol Metab, 2014, 28(3):325-338.
[10] Wu L, Parhofer KG.Diabetic dyslipidemia[J]. Metabolism, 2014, 63(12): 1469-1479.
[11] Baigent C, Blackwell L, Emberson J, et al.Efficacy and safety of more intensive lowering of LDL cholesterol:A meta-analysis of data from 170,000 participants in 26 randomized trials[J].Lancet, 2010, 376(9753): 1670-1681.
[12] Newman CB, Blaha MJ, Boord JB, et al.Lipid management in patients with endocrine disorders: An endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2020, 105(12): 3613-3682.
[13] Pirillo A, Casula M, Catapano AL.European guidelines for the treatment of dyslipidaemias: New concepts and future challenges[J]. Pharmacol Res, 2023, 196: 106936.
[14] 诸骏仁,高润霖,赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016, 44(10): 833-853.
[15] 梁学军,巩纯秀,刘莹,等.儿童2型糖尿病合并高尿酸血症与胰岛素抵抗、血脂关系的研究[J]. 中国糖尿病杂志, 2015, 23(8): 726-729.
[16] 李文明,于超,余雪梅,等. 糖尿病患者血糖控制与血脂的关系[J]. 中国生化药物杂志, 2015, 35(2): 126-129.
[17] Taskinen MR, Borén J.New insights into the pathophysiology of dyslipidemia in type 2 diabetes[J]. Atherosclerosis, 2015, 239(2): 483-495.
[18] Ng DS.Diabetic dyslipidemia: From evolving pathophysiological insight to emerging therapeutic targets[J]. Can J Diabetes, 2013, 37(5): 319-326.
[19] Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus[J]. Int J Mol Sci, 2020; 21(17): 6275. |
